Mouse Anti-RANKL Recombinant Antibody (clone IK22-5) (CAT#: FAMAB-1540CQ)

Figure 1 Specific binding of IK22-5 and IK36-20 to mouse RANKL.

NRK and mouse RANKL-transfected NRK cells were stained with IK22-5 and IK36-20 or RANK-Ig followed by PE-anti-rat IgG Abor PE-anti-human IgG Ab, respectively. Samples were analyzed by flow cytometry. Histograms from the cells stained with control Ig (rat IgG2a or humanIgG1) are overlaid.

Kamijo, S., Nakajima, A., Ikeda, K., Aoki, K., Ohya, K., Akiba, H., ... & Okumura, K. (2006). Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody. Biochemical and biophysical research communications, 347(1), 124-132.

Figure 2 Administration of anti-RANKL mAb did not affect the development of CIA.

DBA/1 mice (n = 10 for each group) were immunized with bovine CII (200 ug/mouse) in CFA. On day 21, the mice were boosted by i.d. injection of CII in CFA. Starting from the day of booster immunization, these mice were i.p. administered with either anti-RANKL mAb(300 ug/mouse) or control IgG (300 ug/mouse) three times a week for 2 weeks. The development of CIA was evaluated. Data are shown as means ± SEM of clinical scores at the indicated times after the booster immunization and are representative of three independent experiments with similar results.

Kamijo, S., Nakajima, A., Ikeda, K., Aoki, K., Ohya, K., Akiba, H., ... & Okumura, K. (2006). Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody. Biochemical and biophysical research communications, 347(1), 124-132.

Figure 3 Effect of anti-RANKL mAb treatment on serum CII-specific antibodies.

Sera were collected from individual mice on day 7 after the second immunization. CII-specific antibody levels were measured by subclass-specific ELISA. Data are shown as means ± SEM of five mice in each group. Similar results were obtained in three independent experiments

Kamijo, S., Nakajima, A., Ikeda, K., Aoki, K., Ohya, K., Akiba, H., ... & Okumura, K. (2006). Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody. Biochemical and biophysical research communications, 347(1), 124-132.